Literature DB >> 25569734

Saccharomyces cerevisiae CNCM I-3856 prevents colitis induced by AIEC bacteria in the transgenic mouse model mimicking Crohn's disease.

Adeline Sivignon1, Amélie de Vallée, Nicolas Barnich, Jérémy Denizot, Claude Darcha, Georges Pignède, Pascal Vandekerckove, Arlette Darfeuille-Michaud.   

Abstract

BACKGROUND: Adherent-invasive Escherichia coli (AIEC), which colonize the ileal mucosa of patients with Crohn's disease (CD), are able to adhere to and invade intestinal epithelial cells. Overexpression of the glycoprotein CEACAM6 on host cells favors AIEC attachment and inflammation. We investigated the ability of Saccharomyces cerevisiae CNCM I-3856 to inhibit AIEC adhesion and to reduce colitis.
METHODS: Adhesion experiments were performed on T84 cells and on enterocytes from patients with CD with AIEC LF82 in the presence of S. cerevisiae. Colonization and symptoms of colitis were assessed in LF82-infected transgenic CEABAC10 mice treated with live S. cerevisiae or S. cerevisiae derivatives. Proinflammatory cytokines were quantified by enzyme linked immunosorbent assay. Intestinal permeability was assessed by measuring the 4 kDa dextran-FITC flux in the serum.
RESULTS: S. cerevisiae strongly inhibited LF82 adhesion to T84 cells and to the brush border of CD enterocytes. Yeasts decreased LF82 colonization and colitis in CEABAC10 mice and restored barrier function through prevention of the LF82-induced expression of pore-forming tight junction claudin-2 at the plasma membrane of intestinal epithelial cells. These effects were accompanied by a decrease in proinflammatory cytokines IL-6, IL-1β, and KC release by the gut mucosa. Yeast derivatives exerted similar effects on LF82 colonization and colitis demonstrating that yeast viability was not essential to exert beneficial effects.
CONCLUSIONS: S. cerevisiae yeasts reduce colitis induced by AIEC bacteria in CEACAM6-expressing mice. Such a probiotic strategy could be envisaged in a subgroup of patients with CD abnormally expressing CEACAM6 at the ileal mucosa and therefore susceptible to being colonized by AIEC bacteria.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25569734     DOI: 10.1097/MIB.0000000000000280

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  22 in total

1.  Professor Arlette Darfeuille-Michaud: the discovery of adherent-invasive Escherichia coli.

Authors:  Ye Yang; Christian Jobin
Journal:  J Crohns Colitis       Date:  2015-03-10       Impact factor: 9.071

Review 2.  Purinergic signaling during intestinal inflammation.

Authors:  Maria Serena Longhi; Alan Moss; Zhenghui Gordon Jiang; Simon C Robson
Journal:  J Mol Med (Berl)       Date:  2017-05-26       Impact factor: 4.599

Review 3.  The microbiome in inflammatory bowel diseases: from pathogenesis to therapy.

Authors:  Sheng Liu; Wenjing Zhao; Ping Lan; Xiangyu Mou
Journal:  Protein Cell       Date:  2020-06-29       Impact factor: 14.870

Review 4.  Understanding host-adherent-invasive Escherichia coli interaction in Crohn's disease: opening up new therapeutic strategies.

Authors:  Allison Agus; Sébastien Massier; Arlette Darfeuille-Michaud; Elisabeth Billard; Nicolas Barnich
Journal:  Biomed Res Int       Date:  2014-12-15       Impact factor: 3.411

5.  Therapeutic activity of a Saccharomyces cerevisiae-based probiotic and inactivated whole yeast on vaginal candidiasis.

Authors:  Eva Pericolini; Elena Gabrielli; Nathalie Ballet; Samuele Sabbatini; Elena Roselletti; Amélie Cayzeele Decherf; Fanny Pélerin; Eugenio Luciano; Stefano Perito; Peter Jüsten; Anna Vecchiarelli
Journal:  Virulence       Date:  2016-07-19       Impact factor: 5.882

6.  A β-Glucan-Based Dietary Fiber Reduces Mast Cell-Induced Hyperpermeability in Ileum From Patients With Crohn's Disease and Control Subjects.

Authors:  John-Peter Ganda Mall; Maite Casado-Bedmar; Martin E Winberg; Robert J Brummer; Ida Schoultz; Åsa V Keita
Journal:  Inflamm Bowel Dis       Date:  2017-12-19       Impact factor: 5.325

7.  Saccharomyces cerevisiae-based probiotic as novel anti-microbial agent for therapy of bacterial vaginosis.

Authors:  Samuele Sabbatini; Claudia Monari; Nathalie Ballet; Paolo Mosci; Amélie Cayzeele Decherf; Fanny Pélerin; Stefano Perito; Paolo Scarpelli; Anna Vecchiarelli
Journal:  Virulence       Date:  2018-12-31       Impact factor: 5.882

8.  Development of Heptylmannoside-Based Glycoconjugate Antiadhesive Compounds against Adherent-Invasive Escherichia coli Bacteria Associated with Crohn's Disease.

Authors:  Adeline Sivignon; Xibo Yan; Dimitri Alvarez Dorta; Richard Bonnet; Julie Bouckaert; Etienne Fleury; Julien Bernard; Sébastien G Gouin; Arlette Darfeuille-Michaud; Nicolas Barnich
Journal:  mBio       Date:  2015-11-17       Impact factor: 7.867

9.  Fungal microbiota dysbiosis in IBD.

Authors:  Harry Sokol; Valentin Leducq; Hugues Aschard; Hang-Phuong Pham; Sarah Jegou; Cecilia Landman; David Cohen; Giuseppina Liguori; Anne Bourrier; Isabelle Nion-Larmurier; Jacques Cosnes; Philippe Seksik; Philippe Langella; David Skurnik; Mathias L Richard; Laurent Beaugerie
Journal:  Gut       Date:  2016-02-03       Impact factor: 23.059

10.  Dynamic In Vitro Models of the Human Gastrointestinal Tract as Relevant Tools to Assess the Survival of Probiotic Strains and Their Interactions with Gut Microbiota.

Authors:  Charlotte Cordonnier; Jonathan Thévenot; Lucie Etienne-Mesmin; Sylvain Denis; Monique Alric; Valérie Livrelli; Stéphanie Blanquet-Diot
Journal:  Microorganisms       Date:  2015-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.